Skip to nav Skip to content
Lubomir  Sokol

Lubomir Sokol, MD, PhD

4.8 (119)

Specialty: Hematology/Oncology

Program: Malignant Hematology

  • Overview

    Cancer Focus:
    Cutaneous Lymphoma (CTCL), Hodgkin Lymphoma, Leukemia, Non-Hodgkin Lymphoma

    Over the past fifteen years, Dr. Sokol's clinical and laboratory work has been focused on T-cell lymphomas and leukemias and rare lymphoproliferative and histiocytic disorders including Castleman disease, Langerhans Cell Histiocytosis, Hemophagocytic LymphoHistiocytosis, Rosai-Dorfman Disease, etc.  He has participated in numerous clinical trials for T cell malignancies including pivotal studies with romidepsin and mogamulizumab. He also led clinical research in T-cell and NK-cell large granular lymphocytic leukemia (LGL). Dr. Sokol has been the Co-Director of the Cutaneous Lymphoma Multidisciplinary Clinic for over 15 years. This clinic is the largest referral center for patients with cutaneous T cell lymphoma (CTCL) in the southeastern U.S. Moffitt's LGL Center belongs among the three largest referral centers for this disease nationally. Dr. Sokol's clinical and laboratory research in the above field is supported with numerous publications in top ranked hematology journals. Dr. Sokol collaborates on clinical and laboratory investigation nationally and internationally. In his role of the Director of hematology/oncology fellowship program he has trained and mentored numerous young physicians in the field of malignant hematology.

    Education & Training

    Board Certification:

    • Internal Medicine - Hematology

    Fellowship:

    • Charles University of Prague, Czechoslovakia - Radiation Oncology
    • Charles University of Prague, Czechoslovakia - Clinical Oncology
    • Czechoslovak Academy of Sciences, Prague, Czechoslovakia - Molecular Genetics
    • University of Alabama, Birmingham, AL - Molecular Biology
    • University of South Florida, Tampa, FL - Medical Oncology/Hematology

    Residency:

    • Charles University of Prague, Czechoslovakia - Radiation Oncology
    • Louisiana State University, Lafayette, LA - Internal Medicine

    Medical School:

    • Charles University of Prague, Czechoslovakia - MD
  • Participating Trials

    Clinical Trial 21143
    A Single-Arm, Open-Label, Pilot Study of Concurrent Phototherapy and POTELIGEO (mogamulizumab-kpkc) in Early Stage Mycosis Fungoides (PLIGHT)
    Condition: Malignant Hematology
    Intervention: KW-0761 (Mogamulizumab); Mogamulizumab ()
    Status: Open

    If you believe you are eligible for one of these trials or studies, please call
    813-745-6100 or toll-free 1-800-679-0775.

  • Publications

    • Dong N, Zhang H, Song J, Mammadova J, Shah B, Saeed H, Gaballa S, Grajales-Cruz A, Isenalumhe L, Bello C, Sokol L, Pinilla J, Chavez J. B-cell maturation antigen expression and clinical features of plasmablastic lymphoma. EJHaem. 2024 Feb.5(1):285-289. Pubmedid: 38406544. Pmcid: PMC10887266.
    • Harro CM, Sprenger KB, Chaurio RA, Powers JJ, Innamarato P, Anadon CM, Zhang Y, Biswas S, Mandal G, Mine JA, Cortina C, Nagy MZ, Martin AL, Handley KF, Borjas GJ, Chen PL, Pinilla-Ibarz J, Sokol L, Yu X, Conejo-Garcia JR. Sézary syndrome originates from heavily mutated hematopoietic progenitors. Blood Adv. 2023 Sep.7(18):5586-5602. Pubmedid: 37531660. Pmcid: PMC10514084.
    • Saeed H, Sandoval-Sus J, Castillo-Tokumori F, Dong N, Pullukkara JJ, Boisclair S, Brahim A, Walker D, Bridgellal S, Zhang L, Sokol L. Poor Outcome of Adult T-Cell Leukemia/Lymphoma with Current Available Therapy: An Experience of Two Centers. Oncol Res Treat. 2023 Oct.1-6. Pubmedid: 37844559.
    • Brammer JE, Ballen K, Sokol L, Querfeld C, Nakamura R, Mishra A, Mclaughlin EM, Feith D, Azimi N, Waldmann T, Tagaya Y, Loughran T. Effective treatment with the selective cytokine inhibitor BNZ-1 reveals the cytokine dependency of T-LGL leukemia. Blood. 2023 Oct.142(15):1271-1280. Pubmedid: 37352612. Pmcid: PMC10613725.
    • Ruan J, Moskowitz AJ, Mehta-Shah N, Sokol L, Chen Z, Kotlov N, Nos G, Sorokina M, Maksimov V, Sboner A, Sigouros M, van Besien K, Horwitz SM, Rutherford SC, Mulvey E, Revuelta MV, Xiang JZ, Alonso A, Melnick AM, Elemento O, Inghirami GG, Leonard JP, Cerchietti L, Martin P. Multicenter phase 2 study of oral azacitidine (CC-486) plus CHOP as initial treatment for PTCL. Blood. 2023 May.141(18):2194-2205. Pubmedid: 36796016.
    • Zhang Y, Nguyen L, Lu CM, Wang E, Lauw MIS, Ball S, Dong N, Moscinski L, Chan O, Yun S, Sallman D, Sokol L, Shah B, Knepper T, Lancet J, Komrokji R, Padron E, Kuykendall A, Zhang L. Clinical Response to Upfront Targeted Tyrosine Kinase Inhibitors among Patients with Myeloid/Lymphoid Neoplasms with Eosinophilia and Tyrosine Kinase Gene Fusion. Clin Lymphoma Myeloma Leuk. 2023 Mar.23(3):e150-e163. Pubmedid: 36624015.
    • Barila' G, Grassi A, Cheon H, Teramo A, Calabretto G, Chahal JS, Vicenzetto C, Almeida J, Shemo BC, Shi M, Gasparini VRR, Munoz-Garcia N, Pastoret C, Nakazawa H, Oshimi K, Sokol L, Ishida F, Lamy T, Orfao A, Morice WG, Loughran T, Semenzato G, Zambello R. Tγδ LGLL identifies a subset with more symptomatic disease: analysis of an international cohort of 137 patients. Blood. 2023 Mar.141(9):1036-1046. Pubmedid: 36096473.
    • Rose A, Zhang L, Jain AG, Poovathukaran Babu A, Sokol L, Saeed H, Mo Q, Fan W, Zhang X. Delineation of clinical course, outcomes, and prognostic factors in patients with T-cell prolymphocytic leukemia. Am J Hematol. 2023 Jun.98(6):913-921. Pubmedid: 36964941.
    • Visweshwar N, Rico JF, Ayala I, Jaglal M, Laber DA, Ammad-Ud-Din M, Sokol L, Sotomayor E, Manoharan A. Insights into the Impact of Hesitancy on Cancer Care and COVID-19. Cancers (Basel). 2023 Jun.15(12). Pubmedid: 37370725. Pmcid: PMC10296298.
    • Shah NN, Castillo-Tokumori F, Whiting J, Boulware D, Sandoval-Sus J, Knepper TC, Hussaini M, Tao J, Chavez JC, Isenalumhe L, Gaballa S, Saeed H, Bello C, Sokol L, Pinilla-Ibarz J, Shah BD. Frontline treatment approaches in TP53-aberrant mantle cell lymphoma. Leuk Lymphoma. 2023 Jan.64(1):230-233. Pubmedid: 36301721.
    • Singh AM, Zhang H, Sokol L. Severe Thrombocytopenia in a Patient With a History of Olfactory Neuroblastoma. Cureus. 2023 Jan.15(1):e33297. Pubmedid: 36741647. Pmcid: PMC9894644.
    • Glinos G, Wei G, Nosewicz J, Abdulla F, Chen PL, Chung C, Kaffenberger BH, Querfeld C, Shinohara MM, Sokol L, Zain J, Kumar A, Seminario-Vidal L. Characteristics and Outcomes for Hospitalized Patients With Cutaneous T-Cell Lymphoma. JAMA Dermatol. 2023 Feb.159(2):192-197. Pubmedid: 36598766. Pmcid: PMC9857769.
    • Azem A, Caddell R, Nelson R, Isenalumhe L, Gaballa S, Chavez J, Bello C, Pinilla J, Sokol L, Shah B, Saeed H. Toxicity of a Modified PEG-Asparaginase-Based SMILE Regimen Is Comparable to L-Asparaginase-Based SMILE in a Non-Asian Population. Clin Lymphoma Myeloma Leuk. 2023 Aug.23(8):606-609. Pubmedid: 37210271.
    • Abramson JS, Bengtson E, Redd RA, Barnes JA, Takvorian T, Sokol L, Lansigan F, Armand P, Shah BD, Jacobsen ED, Martignetti R, Turba E, Metzler S, Patterson V, LaCasce AS, Bello CM. Brentuximab vedotin plus doxorubicin and dacarbazine in nonbulky limited-stage classical Hodgkin lymphoma. Blood Adv. 2023 Apr.7(7):1130-1136. Pubmedid: 36053786. Pmcid: PMC10111342.
    • Visweshwar N, Ayala I, Jaglal M, Killeen R, Sokol L, Laber DA, Manoharan A. Primary immune thrombocytopenia: a 'diagnosis of exclusion'?. Blood Coagul Fibrinolysis. 2022 Sep.33(6):289-294. Pubmedid: 35867940. Pmcid: PMC9415225.
    • Elbaz Younes I, Sokol L, Zhang L. Rosai-Dorfman Disease between Proliferation and Neoplasia. Cancers (Basel). 2022 Oct.14(21). Pubmedid: 36358690. Pmcid: PMC9654168.
    • Song X, Chang S, Seminario-Vidal L, de Mingo Pulido A, Tordesillas L, Song X, Reed RA, Harkins A, Whiddon S, Nguyen JV, Moran Segura C, Zhang C, Yoder S, Sayegh Z, Zhao Y, Messina JL, Harro CM, Zhang X, Conejo-Garcia JR, Berglund AE, Sokol L, Zhang J, Rodriguez PC, Mule JJ, Futreal AP, Tsai KY, Chen PL. Genomic and Single-Cell Landscape Reveals Novel Drivers and Therapeutic Vulnerabilities of Transformed Cutaneous T-cell Lymphoma. Cancer Discov. 2022 May.12(5):1294-1313. Pubmedid: 35247891. Pmcid: PMC9148441.
    • Zhang Y, Seminario-Vidal L, Cohen L, Hussaini M, Yao J, Rutenberg D, Kim Y, Giuliano A, Robinson LA, Sokol L. "Alterations in the Skin Microbiota Are Associated With Symptom Severity in Mycosis Fungoides". Front Cell Infect Microbiol. 2022 May.12:850509. Pubmedid: 35656034. Pmcid: PMC9152451.
    • Horwitz SM, Ansell S, Ai WZ, Barnes J, Barta SK, Brammer J, Clemens MW, Dogan A, Foss F, Ghione P, Goodman AM, Guitart J, Halwani A, Haverkos BM, Hoppe RT, Jacobsen E, Jagadeesh D, Jones A, Kallam A, Kim YH, Kumar K, Mehta-Shah N, Olsen EA, Rajguru SA, Rozati S, Said J, Shaver A, Shea L, Shinohara MM, Sokol L, Torres-Cabala C, Wilcox R, Wu P, Zain J, Dwyer M, Sundar H. T-Cell Lymphomas, Version 2.2022, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Ne. 2022 Mar.20(3):285-308. Pubmedid: 35276674.
    • Zhang Y, Sokol L. Clinical Insights into the Management of Blastic Plasmacytoid Dendritic Cell Neoplasm. Cancer Manag Res. 2022 Jun.14:2107-2117. Pubmedid: 35789956. Pmcid: PMC9250318.
    • Zhang Y, Seminario-Vidal L, Varnadoe C, Lu Y, Dong N, Salamanca C, Whiddon S, Bennett J, Hargis R, Liu H, Montejo M, Hussaini M, Harro C, Messina J, Benson K, Pinilla-Ibarz J, Conejo-Garcia J, Sokol L. Clinical characteristics and prognostic factors of 70 patients with Sézary syndrome: a single-institutional experience at Moffitt cancer center. Leuk Lymphoma. 2022 Jan.63(1):109-116. Pubmedid: 34467825. Pmcid: PMC9167451.
    • Malachowski SJ, Moy A, Messina J, Chen YA, Sun J, Sokol L, Seminario-Vidal L. Mapping cutaneous T-cell lymphoma in the state of Florida: A retrospective exploratory spatial analysis of incidence patterns. J Am Acad Dermatol. 2022 Jan.86(1):186-188. Pubmedid: 33476732.
    • Bagot M, Dalle S, Sokol L, Tsianakas A, Musiek A, Ortiz-Romero PL, Poligone B, Duvic M, Elmets C, Leoni M, Dwyer K, Ito T, Herr F, Kim YH. Long-term disease control and safety with the anti-CCR4 antibody mogamulizumab: Post-hoc analyses from the MAVORIC trial of patients with previously treated cutaneous T-cell lymphoma. Dermatol Ther. 2022 Aug.35(8):e15634. Pubmedid: 35695215. Pmcid: PMC9539986.
    • Mushtaq S, Prabakaran S, Elharake M, Mirza S, Ravindran A, Faramand R, Sokol L. Primary Effusion Lymphoma: Small Bowel Recurrence After Stem Cell Transplant. ACG Case Rep J. 2021 Nov.8(11):e00698. Pubmedid: 34820467. Pmcid: PMC8608261.
    • Cowan R, Scarisbrick JJ, Zinzani PL, Nicolay JP, Sokol L, Pinter-Brown L, Quaglino P, Iversen L, Dummer R, Musiek A, Foss F, Ito T, Rosen JP, Medley MC. Efficacy and safety of mogamulizumab by patient baseline blood tumour burden: a post hoc analysis of the MAVORIC trial. J Eur Acad Dermatol Venereol. 2021 Nov.35(11):2225-2238. Pubmedid: 34273208. Pmcid: PMC9290719.
    • Gesiotto Q, Zhang Y, Malik A, Seminario-Vidal L, Ayala E, Zhang L, Sokol L. Long-Term Remission After Matched Sibling Donor Hematopoietic Cell Transplantation in a Patient With Primary Cutaneous CD8+ Aggressive Epidermotropic Cytotoxic T-Cell Lymphoma. Cureus. 2021 May.13(5):e15132. Pubmedid: 34159034. Pmcid: PMC8214246.
    • Visweshwar N, Jaglal M, Patel A, Laber D, Sokol L. Should we integrate viscoelastic assays with standard coagulation screening?. J Clin Pathol. 2021 Mar.74(3):141-143. Pubmedid: 33436484.
    • Dong N, Castillo Tokumori F, Isenalumhe L, Zhang Y, Tandon A, Knepper TC, Mo Q, Shao H, Zhang L, Sokol L. Large granular lymphocytic leukemia - A retrospective study of 319 cases. Am J Hematol. 2021 Jul.96(7):772-780. Pubmedid: 33819354.
    • Shah NN, Sokol L. Targeting CD22 for the Treatment of B-Cell Malignancies. Immunotargets Ther. 2021 Jul.10:225-236. Pubmedid: 34262884. Pmcid: PMC8275043.
    • Gibbs JD, Ma S, Kim A, Seminario-Vidal L, Sokol L, Zhang H, Zhang X, Sagatys E, Chen PL, Messina JL. Utility of flow cytometry and gene rearrangement analysis in tissue and blood of patients with suspected cutaneous T‑cell lymphoma. Oncol Rep. 2021 Jan.45(1):349-358. Pubmedid: 33416132.
    • Rose A, Grajales-Cruz A, Lim A, Todd A, Bello C, Shah B, Chavez J, Pinilla-Ibartz J, Saeed H, Sandoval-Sus J, Isenalumhe L, Sokol L. Classical Hodgkin Lymphoma: Clinicopathologic Features, Prognostic Factors, and Outcomes From a 28-Year Single Institutional Experience. Clin Lymphoma Myeloma Leuk. 2021 Feb.21(2):132-138. Pubmedid: 32950461.
    • Harro CM, Perez-Sanz J, Costich TL, Payne KK, Anadon Galindo CM, Chaurio RA, Biswas S, Mandal G, Rigolizzo KE, Sprenger KB, Mine JA, Showe L, Yu X, Liu K, Rodriguez PC, Pinilla-Ibarz J, Sokol L, Conejo-Garcia JR. Methyltransferase inhibitors restore SATB1 protective activity against cutaneous T cell lymphoma in mice. J Clin Invest. 2021 Feb.131(3). Pubmedid: 33270606. Pmcid: PMC7843215.
    • Zhang Y, Lee D, Gesiotto Q, Sokol L. Aggressive natural killer cell leukemia: diagnosis, treatment recommendations, and emerging therapies. Expert Rev Hematol. 2021 Aug.14(8):731-740. Pubmedid: 34263714.
    • Saeed H, Sokol L. Extranodal NK/T Cell Lymphoma: Evidence-based Review of Safety and Toxicity of the Available Regimens. Clin Lymphoma Myeloma Leuk. 2021 Apr.21(4):199-204. Pubmedid: 33129745.
    • Daou H, Hatch LA, Weinkle A, Morey GE, Messina J, Zhang X, Sokol L, Seminario-Vidal L. CD8-positive cutaneous lymphoproliferation associated with large granular lymphocyte leukemia in a patient with X-linked agammaglobulinemia. J Cutan Pathol. 2021 Apr.48(4):567-571. Pubmedid: 32885480.
    • Falchi L, Ma H, Klein S, Lue JK, Montanari F, Marchi E, Deng C, Kim HA, Rada AM, Jacob AT, Kinahan C, Francescone M, Soderquist CR, Park DC, Bhagat G, Nandakumar R, Menezes DL, Scotto L, Sokol L, Shustov AR, O'Connor OA. Combined oral 5-azacytidine and romidepsin are highly effective in patients with PTCL: a multicenter phase 2 study. Blood. 2021 Apr.137(16):2161-2170. Pubmedid: 33171487.
    • Khadilkar AC, Adashek JJ, Riddle ND, Sokol L. Primary Cutaneous Gamma/Delta T-cell Lymphoma and Hemophagocytic Lymphohistiocytosis Associated With AIDS. Cureus. 2020 Sep.12(9):e10386. Pubmedid: 33062507. Pmcid: PMC7549995.
    • Zhang Y, Varnadoe C, Tandon A, Forsyth P, Komrokji R, Sokol L. Myasthenia Gravis and Large Granular Lymphocytic Leukemia: a rare association. Leuk Res Rep. 2020 Oct.14:100226. Pubmedid: 33094093. Pmcid: PMC7568180.
    • Komrokji RS, Ali NA, Sallman D, Padron E, Lancet J, Sokol L, Varnadoe C, Burnette PK, List A. Characterization of myelodysplastic syndromes (MDS) with T-cell large granular lymphocyte proliferations (LGL). Leukemia. 2020 Nov.34(11):3097-3099. Pubmedid: 32565544.
    • Horwitz SM, Ansell S, Ai WZ, Barnes J, Barta SK, Clemens MW, Dogan A, Goodman AM, Goyal G, Guitart J, Halwani A, Haverkos BM, Hoppe RT, Jacobsen E, Jagadeesh D, Jones A, Kim YH, Mehta-Shah N, Olsen EA, Pro B, Rajguru SA, Rozati S, Said J, Shaver A, Shustov A, Sokol L, Torka P, Torres-Cabala C, Wilcox R, William BM, Zain J, Dwyer MA, Sundar H. NCCN Guidelines Insights: T-Cell Lymphomas, Version 1.2021. J Natl Compr Canc Ne. 2020 Nov.18(11):1460-1467. Pubmedid: 33152703.
    • Mehta-Shah N, Horwitz SM, Ansell S, Ai WZ, Barnes J, Barta SK, Clemens MW, Dogan A, Fisher K, Goodman AM, Goyal G, Guitart J, Halwani A, Haverkos BM, Hoppe RT, Jacobsen E, Jagadeesh D, Lunning MA, Mehta A, Olsen EA, Pro B, Rajguru SA, Shanbhag S, Shaver A, Shustov A, Sokol L, Torka P, Torres-Cabala C, Wilcox R, William BM, Zain J, Dwyer MA, Sundar H, Kim YH. NCCN Guidelines Insights: Primary Cutaneous Lymphomas, Version 2.2020. J Natl Compr Canc Ne. 2020 May.18(5):522-536. Pubmedid: 32380458.
    • Zhang Y, Lee D, Brimer T, Hussaini M, Sokol L. Genomics of Peripheral T-Cell Lymphoma and Its Implications for Personalized Medicine. Front Oncol. 2020 Jun.10:898. Pubmedid: 32637355. Pmcid: PMC7317006.
    • Yun S, Chan O, Kerr D, Vincelette ND, Idrees A, Mo Q, Sweet K, Lancet JE, Kharfan-Dabaja MA, Zhang L, Sokol L. Survival outcomes in blastic plasmacytoid dendritic cell neoplasm by first-line treatment and stem cell transplant. Blood Adv. 2020 Jul.4(14):3435-3442. Pubmedid: 32722779. Pmcid: PMC7391135.
    • Malachowski SJ, Hatch LA, Sokol L, Messina J, Seminario-Vidal L. Pembrolizumab-associated tumor development in a patient with Sézary syndrome. JAAD Case Rep. 2020 Jan.6(1):16-18. Pubmedid: 31909130. Pmcid: PMC6938917.
    • Zhang Y, Song J, Rutenberg D, Sokol L. Hepatic Infiltration with Malignant T-cells Manifesting as Impending Acute Liver Failure in Sezary Syndrome. Mediterr J Hematol Infect Dis. 2020 Jan.12(1):e2020007. Pubmedid: 31934317. Pmcid: PMC6951350.
    • Khodadoust MS, Rook AH, Porcu P, Foss F, Moskowitz AJ, Shustov A, Shanbhag S, Sokol L, Fling SP, Ramchurren N, Pierce R, Davis A, Shine R, Li S, Fong S, Kim J, Yang Y, Blumenschein WM, Yearley JH, Das B, Patidar R, Datta V, Cantu E, McCutcheon JN, Karlovich C, Williams PM, Subrahmanyam PB, Maecker HT, Horwitz SM, Sharon E, Kohrt HE, Cheever MA, Kim YH. Pembrolizumab in Relapsed and Refractory Mycosis Fungoides and Sézary Syndrome: A Multicenter Phase II Study. J Clin Oncol. 2020 Jan.38(1):20-28. Pubmedid: 31532724. Pmcid: PMC6943974.
    • Skelton WP, Turba E, Sokol L. Durable Complete Response to AMG 655 (Conatumumab) and Vorinostat in a Patient With Relapsed Classical Hodgkin Lymphoma: Extraordinary Response from a Phase 1b Clinical Protocol. Clin Lymphoma Myeloma Leuk. 2020 Dec.20(12):e944-e946. Pubmedid: 32828719.
    • Mirza AS, Horna P, Teer JK, Song J, Akabari R, Hussaini M, Sokol L. New Insights Into the Complex Mutational Landscape of Sézary Syndrome. Front Oncol. 2020 Apr.10:514. Pubmedid: 32373524. Pmcid: PMC7186303.
    • Mirza AS, Dholaria BR, Hussaini M, Mushtaq S, Horna P, Ravindran A, Kumar A, Ayala E, Kharfan-Dabaja MA, Bello C, Chavez JC, Sokol L. High-dose Therapy and Autologous Hematopoietic Cell Transplantation as Consolidation Treatment for Primary Effusion Lymphoma. Clin Lymphoma Myeloma Leuk. 2019 Sep.19(9):e513-e520. Pubmedid: 31253594.
    • Visweshwar N, Jaglal M, Sokol L, Djulbegovic B. Hematological Malignancies and Arterial Thromboembolism. Indian J Hematol Blood Transfus. 2019 Oct.35(4):611-624. Pubmedid: 31741612. Pmcid: PMC6825093.
    • O'Connor OA, Falchi L, Lue JK, Marchi E, Kinahan C, Sawas A, Deng C, Montanari F, Amengual JE, Kim HA, Rada AM, Khan K, Jacob AT, Malanga M, Francescone M, Nandakumar R, Soderquist C, Park DC, Bhagat G, Cheng B, Risueno A, Menezes D, Shustov AR, Sokol L, Scotto L. Oral 5-azacytidine and romidepsin exhibit marked activity in patients with PTCL: a multicenter phase 1 study. Blood. 2019 Oct.134(17):1395-1405. Pubmedid: 31471376.
    • McGraw KL, Cheng CH, Chen YA, Hou HA, Nilsson B, Genovese G, Cluzeau T, Pellagatti A, Przychodzen BP, Mallo M, Arenillas L, Mohamedali A, Adès L, Sallman DA, Padron E, Sokol L, Moreilhon C, Raynaud S, Tien HF, Boultwood J, Ebert BL, Sole F, Fenaux P, Mufti GJ, Maciejewski JP, Kanetsky PA, List AF. Non-del(5q) myelodysplastic syndromes-associated loci detected by SNP-array genome-wide association meta-analysis. Blood Adv. 2019 Nov.3(22):3579-3589. Pubmedid: 31738830. Pmcid: PMC6880887.
    • Horna P, Moscinski LC, Sokol L, Shao H. Naïve/memory T-cell phenotypes in leukemic cutaneous T-cell lymphoma: Putative cell of origin overlaps disease classification. Cytometry B Clin Cytom. 2019 May.96(3):234-241. Pubmedid: 30328260. Pmcid: PMC7703846.
    • Ashraf N, Visweshwar N, Jaglal M, Sokol L, Laber D. Evolving paradigm in thrombophilia screening. Blood Coagul Fibrinolysis. 2019 Jul.30(5):249-252. Pubmedid: 31145103. Pmcid: PMC6687403.
    • Sandoval-Sus JD, Faramand R, Chavez J, Puri S, Parra P, Sokol L, Kharfan-Dabaja MA, Shah B, Ayala E. Allogeneic hematopoietic cell transplantation is potentially curative in mantle cell lymphoma: results from a single institution study. Leuk Lymphoma. 2019 Feb.60(2):309-316. Pubmedid: 29963932.
    • Kerr D, Zhang L, Sokol L. Blastic Plasmacytoid Dendritic Cell Neoplasm. CURR TREAT OPTION ON. 2019 Feb.20(1):9. Pubmedid: 30715612.
    • Tandon A, Zhang Y, Sokol L. Tagraxofusp, a novel CD123-directed cytotoxin to treat blastic plasmacytoid dendritic cell neoplasm. Drugs Today (Barc). 2019 Dec.55(12):735-742. Pubmedid: 31942876.
    • Abramson JS, Arnason JE, LaCasce AS, Redd R, Barnes JA, Sokol L, Joyce R, Avigan D, Neuberg D, Takvorian RW, Hochberg EP, Bello CM. Brentuximab vedotin, doxorubicin, vinblastine, and dacarbazine for nonbulky limited-stage classical Hodgkin lymphoma. Blood. 2019 Aug.134(7):606-613. Pubmedid: 31186274.
    • Cohen L, Chen PL, Zhang L, Sokol L, Seminario-Vidal L. Skin-first nodulotumoral adult T-cell lymphoma mimicking cutaneous T-cell lymphoma. JAAD Case Rep. 2019 Aug.5(8):650-652. Pubmedid: 31388529. Pmcid: PMC6677771.
    • Cohen L, Haque A, Ma S, Zhang L, Sokol L, Seminario-Vidal L. T-cell prolymphocytic leukemia presenting with erythematous patches, plaques, and erythema gyratum-like lesions masquerading as Sézary syndrome. JAAD Case Rep. 2019 Aug.5(8):686-690. Pubmedid: 31440557. Pmcid: PMC6698441.
    • Yazbeck V, Shafer D, Perkins EB, Coppola D, Sokol L, Richards KL, Shea T, Ruan J, Parekh S, Strair R, Flowers C, Morgan D, Kmieciak M, Bose P, Kimball A, Badros AZ, Baz R, Lin HY, Zhao X, Reich RR, Tombes MB, Shrader E, Sankala H, Roberts JD, Sullivan D, Grant S, Holkova B. A Phase II Trial of Bortezomib and Vorinostat in Mantle Cell Lymphoma and Diffuse Large B-cell Lymphoma. Clin Lymphoma Myeloma Leuk. 2018 Sep.18(9):569-575.e1. Pubmedid: 30122201.
    • Basiorka AA, McGraw KL, Abbas-Aghababazadeh F, McLemore AF, Vincelette ND, Ward GA, Eksioglu EA, Sallman DA, Ali NA, Padron E, Pinilla-Ibarz J, Komrokji R, Masala E, Santini V, Kosmider O, Fontenay M, Fenaux P, Sokol L, Wei S, Fridley B, List AF. Assessment of ASC specks as a putative biomarker of pyroptosis in myelodysplastic syndromes: an observational cohort study. Lancet Haematol. 2018 Sep.5(9):e393-e402. Pubmedid: 30072146. Pmcid: PMC6505461.
    • Kim YH, Bagot M, Pinter-Brown L, Rook AH, Porcu P, Horwitz SM, Whittaker S, Tokura Y, Vermeer M, Zinzani PL, Sokol L, Morris S, Kim EJ, Ortiz-Romero PL, Eradat H, Scarisbrick J, Tsianakas A, Elmets C, Dalle S, Fisher DC, Halwani A, Poligone B, Greer J, Fierro MT, Khot A, Moskowitz AJ, Musiek A, Shustov A, Pro B, Geskin LJ, Dwyer K, Moriya J, Leoni M, Humphrey JS, Hudgens S, Grebennik DO, Tobinai K, Duvic M. Mogamulizumab versus vorinostat in previously treated cutaneous T-cell lymphoma (MAVORIC): an international, open-label, randomised, controlled phase 3 trial. Lancet Oncol. 2018 Sep.19(9):1192-1204. Pubmedid: 30100375.
    • Kerr Ii D, Sokol L. The advances in therapy of blastic plasmacytoid dendritic cell neoplasm. Expert Opin Inv Drug. 2018 Sep.27(9):733-739. Pubmedid: 30118336.
    • Yun S, Sokol L, Zhang L. Disseminated Cutaneous Lesions in a Patient With a Medical History of Myelodysplastic Syndrome. JAMA Oncol. 2018 Sep.4(9):1281-1282. Pubmedid: 29800978.
    • Afiat TP, Zhang X, Zhang H, Ayala E, Zhang L, Sokol L. Sezary syndrome manifesting as posttransplant lymphoproliferative disorder. Leuk Res Rep. 2018 May.9:72-75. Pubmedid: 29761072. Pmcid: PMC5948470.
    • Rose A, Isenalumhe L, Van den Bergh M, Sokol L. Clonal T-cell Large Granular Lymphocytic Disorders Manifesting in Patients with HIV-1 Infection: Case Series and Review of the Literature. Mediterr J Hematol Infect Dis. 2018 Jun.10(1):e2018036. Pubmedid: 30002792. Pmcid: PMC6039084.
    • Juárez-Salcedo LM, Sokol L, Chavez JC, Dalia S. Primary Gastric Lymphoma, Epidemiology, Clinical Diagnosis, and Treatment. Cancer Control. 2018 Jan.25(1). Pubmedid: 29779412. Pmcid: PMC6028178.
    • Kelling M, Sokol L, Dalia S. Hepatitis B Reactivation in the Treatment of Non-Hodgkin Lymphoma. Cancer Control. 2018 Jan.25(1). Pubmedid: 29606020. Pmcid: PMC6852364.
    • Visweshwar N, Jaglal M, Sokol L, Zuckerman K. Chemotherapy-related anemia. Ann Hematol. 2018 Feb.97(2):375-376. Pubmedid: 29103107.
    • Markow M, Mirza AS, Perez L, Shao H, Horna P, Anasetti C, Sokol L, Hussaini MO. Transformation of T-Cell Acute Lymphoblastic Lymphoma to Peripheral T-Cell Lymphoma: A Report of Two Cases. Case Rep Hematol. 2018 Feb.2018:9191582. Pubmedid: 29682368. Pmcid: PMC5850893.
    • Horwitz SM, Ansell SM, Ai WZ, Barnes J, Barta SK, Choi M, Clemens MW, Dogan A, Greer JP, Halwani A, Haverkos BM, Hoppe RT, Jacobsen E, Jagadeesh D, Kim YH, Lunning MA, Mehta A, Mehta-Shah N, Oki Y, Olsen EA, Pro B, Rajguru SA, Shanbhag S, Shustov A, Sokol L, Torka P, Wilcox R, William B, Zain J, Dwyer MA, Sundar H. NCCN Guidelines Insights: T-Cell Lymphomas, Version 2.2018. J Natl Compr Canc Ne. 2018 Feb.16(2):123-135. Pubmedid: 29439173.
    • Dholaria BR, Ayala E, Sokol L, Nishihori T, Chavez JC, Hussaini M, Kumar A, Kharfan-Dabaja MA. Allogeneic hematopoietic cell transplantation in T-cell prolymphocytic leukemia: A single-center experience. Leuk Res. 2018 Apr.67:1-5. Pubmedid: 29407180.
    • Foss F, Horwitz S, Pro B, Miles Prince H, Sokol L, Balser B, Wolfson J, Coiffier B. Erratum to: Romidepsin for the treatment of relapsed/refractory peripheral T cell lymphoma: prolonged stable disease provides clinical benefits for patients in the pivotal trial. J Hematol Oncol. 2017 Sep.10(1):154. Pubmedid: 28923081. Pmcid: PMC5603163.
    • Bohra C, Sokol L, Dalia S. Progressive Multifocal Leukoencephalopathy and Monoclonal Antibodies: A Review. Cancer Control. 2017 Oct.24(4). Pubmedid: 28975841. Pmcid: PMC5937251.
    • Shustov A, Coiffier B, Horwitz S, Sokol L, Pro B, Wolfson J, Balser B, Eisch R, Popplewell L, Prince HM, Allen SL, Piekarz R, Bates S. Romidepsin is effective and well tolerated in older patients with peripheral T-cell lymphoma: analysis of two phase II trials. Leuk Lymphoma. 2017 Oct.58(10):2335-2341. Pubmedid: 28264616.
    • Kharfan-Dabaja MA, Kumar A, Ayala E, Hamadani M, Reimer P, Gisselbrecht C, d'Amore F, Jantunen E, Ishida T, Bazarbachi A, Foss F, Advani R, Fenske TS, Lazarus HM, Friedberg JW, Aljurf M, Sokol L, Tobinai K, Tse E, Burns LJ, Chavez JC, Reddy NM, Suzuki R, Ahmed S, Nademanee A, Mohty M, Gopal AK, Fanale MA, Pro B, Moskowitz AJ, Sureda A, Perales MA, Carpenter PA, Savani BN. Clinical Practice Recommendations on Indication and Timing of Hematopoietic Cell Transplantation in Mature T Cell and NK/T Cell Lymphomas: An International Collaborative Effort on Behalf of the Guidelines Committee of the American Society for Blood and Ma. Biol Blood Marrow Tr. 2017 Nov.23(11):1826-1838. Pubmedid: 28797780.
    • Juárez-Salcedo LM, Sandoval-Sus J, Sokol L, Chavez JC, Dalia S. The role of anti-PD-1 and anti-PD-L1 agents in the treatment of diffuse large B-cell lymphoma: The future is now. Crit Rev Oncol Hematol. 2017 May.113:52-62. Pubmedid: 28427522.
    • Wierda WG, Zelenetz AD, Gordon LI, Abramson JS, Advani RH, Andreadis CB, Bartlett N, Byrd JC, Caimi P, Fayad LE, Fisher RI, Glenn MJ, Habermann TM, Harris NL, Hernandez-Ilizaliturri F, Hoppe RT, Horwitz SM, Kaminski MS, Kelsey CR, Kim YH, Krivacic S, LaCasce AS, Martin MG, Nademanee A, Porcu P, Press O, Rabinovitch R, Reddy N, Reid E, Roberts K, Saad AA, Snyder ED, Sokol L, Swinnen LJ, Vose JM, Yahalom J, Dwyer MA, Sundar H. NCCN Guidelines Insights: Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Version 1.2017. J Natl Compr Canc Ne. 2017 Mar.15(3):293-311. Pubmedid: 28275031.
    • Foss F, Pro B, Miles Prince H, Sokol L, Caballero D, Horwitz S, Coiffier B. Responses to romidepsin by line of therapy in patients with relapsed or refractory peripheral T-cell lymphoma. Cancer Med. 2017 Jan.6(1):36-44. Pubmedid: 27981793. Pmcid: PMC5269566.
    • Ozoya OO, Chavez J, Sokol L, Dalia S. Optimizing antiviral agents for hepatitis B management in malignant lymphomas. Ann Transl Med. 2017 Feb.5(3):39. Pubmedid: 28251118. Pmcid: PMC5326643.
    • Kharfan-Dabaja MA, Al Malki MM, Deotare U, Raj RV, El-Jurdi N, Majhail N, Cherry MA, Bashir Q, Darrah J, Nishihori T, Sibai H, Hamadani M, de Lima M, Gerds AT, Selby G, Qazilbash MH, Forman SJ, Ayala E, Lipton JH, Hari PN, Muzzafar T, Zhang L, Olteanu H, Perkins J, Sokol L, Kumar A, Ahmed S. Haematopoietic cell transplantation for blastic plasmacytoid dendritic cell neoplasm: a North American multicentre collaborative study. Brit J Haematol. 2017 Dec.179(5):781-789. Pubmedid: 28980314.
    • Pro B, Horwitz SM, Prince HM, Foss FM, Sokol L, Greenwood M, Caballero D, Morschhauser F, Wilhelm M, Iyer SP, Shustov AR, Wolfson J, Balser BE, Coiffier B. Romidepsin induces durable responses in patients with relapsed or refractory angioimmunoblastic T-cell lymphoma. Hematol Oncol. 2017 Dec.35(4):914-917. Pubmedid: 27402335. Pmcid: PMC5763404.
    • Zhang L, Van den Bergh M, Sokol L. CD4-Positive T-Cell Large Granular Lymphocytosis Mimicking Sezary Syndrome in a Patient With Mycosis Fungoides. Cancer Control. 2017 Apr.24(2):207-212. Pubmedid: 28441377.
    • Tees MT, Sokol L. Novel Immunotherapies for B-Cell Lymphomas and Leukemias. Am J Ther. 2016 Sep.23(5):e1157-e1181. Pubmedid: 25237982.
    • Horwitz SM, Zelenetz AD, Gordon LI, Wierda WG, Abramson JS, Advani RH, Andreadis CB, Bartlett N, Byrd JC, Fayad LE, Fisher RI, Glenn MJ, Habermann TM, Lee Harris N, Hernandez-Ilizaliturri F, Hoppe RT, Kaminski MS, Kelsey CR, Kim YH, Krivacic S, LaCasce AS, Lunning M, Nademanee A, Press O, Rabinovitch R, Reddy N, Reid E, Roberts K, Saad AA, Sokol L, Swinnen LJ, Vose JM, Yahalom J, Zafar N, Dwyer M, Sundar H, Porcu P. NCCN Guidelines Insights: Non-Hodgkin's Lymphomas, Version 3.2016. J Natl Compr Canc Ne. 2016 Sep.14(9):1067-1079. Pubmedid: 27587620.
    • Ozoya OO, Sokol L, Dalia S. EBV-Related Malignancies, Outcomes and Novel Prevention Strategies. Infect Disord Drug Targets. 2016 May.16(1):4-21. Pubmedid: 27052336.
    • Tees MT, Sokol L. Novel Pharmacotherapies for B-Cell Lymphomas and Leukemias. Am J Ther. 2016 Mar.23(2):e498-e520. Pubmedid: 25549076.
    • Foss F, Horwitz S, Pro B, Prince HM, Sokol L, Balser B, Wolfson J, Coiffier B. Romidepsin for the treatment of relapsed/refractory peripheral T cell lymphoma: prolonged stable disease provides clinical benefits for patients in the pivotal trial. J Hematol Oncol. 2016 Mar.9:22. Pubmedid: 26965915. Pmcid: PMC4785666.
    • Basiorka AA, McGraw KL, De Ceuninck L, Griner LN, Zhang L, Clark JA, Caceres G, Sokol L, Komrokji RS, Reuther GW, Wei S, Tavernier J, List AF. Lenalidomide Stabilizes the Erythropoietin Receptor by Inhibiting the E3 Ubiquitin Ligase RNF41. Cancer Res. 2016 Jun.76(12):3531-3540. Pubmedid: 27197154. Pmcid: PMC4911265.
    • Apuri S, Sokol L. An overview of investigational Histone deacetylase inhibitors (HDACis) for the treatment of non-Hodgkin's lymphoma. Expert Opin Inv Drug. 2016 Jun.25(6):687-696. Pubmedid: 26954526.
    • Ozoya OO, Sokol L, Dalia S. Hepatitis B Reactivation with Novel Agents in Non-Hodgkin's Lymphoma and Prevention Strategies. J Clin Transl Hepatol. 2016 Jun.4(2):143-150. Pubmedid: 27350944. Pmcid: PMC4913070.
    • Jeong D, Choi JW, Jeong K, Sokol L. CT findings associated with blastic plasmacytoid dendritic cell neoplasm: a case report. Acta Radiol Open. 2016 Jul.5(7):2058460116657688. Pubmedid: 27504192. Pmcid: PMC4963986.
    • Zelenetz AD, Gordon LI, Wierda WG, Abramson JS, Advani RH, Andreadis CB, Bartlett N, Byrd JC, Fayad LE, Fisher RI, Glenn MJ, Habermann TM, Lee Harris N, Hernandez-Ilizaliturri F, Hoppe RT, Horwitz SM, Kaminski MS, Kelsey CR, Kim YH, Krivacic S, LaCasce AS, Lunning M, Nademanee A, Porcu P, Press O, Rabinovitch R, Reddy N, Reid E, Roberts K, Saad AA, Sokol L, Swinnen LJ, Vose JM, Yahalom J, Zafar N, Dwyer M, Sundar H. Diffuse Large B-Cell Lymphoma Version 1.2016. J Natl Compr Canc Ne. 2016 Feb.14(2):196-231. Pubmedid: 26850490.
    • Basiorka AA, McGraw KL, Eksioglu EA, Chen X, Johnson J, Zhang L, Zhang Q, Irvine BA, Cluzeau T, Sallman DA, Padron E, Komrokji R, Sokol L, Coll RC, Robertson AA, Cooper MA, Cleveland JL, O'Neill LA, Wei S, List AF. The NLRP3 inflammasome functions as a driver of the myelodysplastic syndrome phenotype. Blood. 2016 Dec.128(25):2960-2975. Pubmedid: 27737891. Pmcid: PMC5179338.
    • Roe C, Komrokji R, Zhang L, Price S, Sokol L. Adult T-Cell Leukemia/Lymphoma: Rarely Encountered in the United States. Clin Lymphoma Myeloma Leuk. 2016 Aug.16 Suppl:S191-S194. Pubmedid: 27521318.
    • Chavez JC, Piris-Villaespesa M, Dalia S, Powers J, Turba E, Nodzon L, Komrokji R, Sokol L, Locke FL, Lancet J, Sotomayor EM, Kharfan-Dabaja MA, Pinilla-Ibarz J. Results of a phase II study of lenalidomide and rituximab for refractory/relapsed chronic lymphocytic leukemia. Leuk Res. 2016 Aug.47:78-83. Pubmedid: 27285853.
    • Chavez JC, Sandoval-Sus J, Horna P, Dalia S, Bello C, Chevernick P, Sotomayor EM, Sokol L, Shah B. Lymphomatoid Granulomatosis: A Single Institution Experience and Review of the Literature. Clin Lymphoma Myeloma Leuk. 2016 Aug.16 Suppl:S170-S174. Pubmedid: 27521314.
    • Zhang X, Sokol L, Bennett JM, Moscinski LC, List A, Zhang L. T-cell large granular lymphocyte proliferation in myelodysplastic syndromes: Clinicopathological features and prognostic significance. Leuk Res. 2016 Apr.43:18-23. Pubmedid: 26927701.
    • McGraw KL, Cluzeau T, Sallman DA, Basiorka AA, Irvine BA, Zhang L, Epling-Burnette PK, Rollison DE, Mallo M, Sokol L, Solé F, Maciejewski J, List AF. TP53 and MDM2 single nucleotide polymorphisms influence survival in non-del(5q) myelodysplastic syndromes. Oncotarget. 2015 Oct.6(33):34437-34445. Pubmedid: 26416416. Pmcid: PMC4741464.
    • Ozoya OO, Sokol L, Dalia S. "EBV-related Malignancies, Outcomes and Novel Prevention Strategies". Infect Disord Drug Targets. 2015 Nov. Pubmedid: 26585986.
    • Zelenetz AD, Gordon LI, Wierda WG, Abramson JS, Advani RH, Andreadis CB, Bartlett N, Byrd JC, Czuczman MS, Fayad LE, Fisher RI, Glenn MJ, Habermann TM, Harris NL, Hoppe RT, Horwitz SM, Kelsey CR, Kim YH, Krivacic S, LaCasce AS, Nademanee A, Porcu P, Press O, Rabinovitch R, Reddy N, Reid E, Saad AA, Sokol L, Swinnen LJ, Tsien C, Vose JM, Wilson L, Yahalom J, Zafar N, Dwyer M, Sundar H. Chronic lymphocytic leukemia/small lymphocytic lymphoma, version 1.2015. J Natl Compr Canc Ne. 2015 Mar.13(3):326-362. Pubmedid: 25736010. Pmcid: PMC4841457.
    • Duvic M, Pinter-Brown LC, Foss FM, Sokol L, Jorgensen JL, Challagundla P, Dwyer KM, Zhang X, Kurman MR, Ballerini R, Liu L, Kim YH. Phase 1/2 study of mogamulizumab, a defucosylated anti-CCR4 antibody, in previously treated patients with cutaneous T-cell lymphoma. Blood. 2015 Mar.125(12):1883-1889. Pubmedid: 25605368. Pmcid: PMC4375715.
    • McGraw KL, Zhang LM, Rollison DE, Basiorka AA, Fulp W, Rawal B, Jerez A, Billingsley DL, Lin HY, Kurtin SE, Yoder S, Zhang Y, Guinta K, Mallo M, Solé F, Calasanz MJ, Cervera J, Such E, González T, Nevill TJ, Haferlach T, Smith AE, Kulasekararaj A, Mufti G, Karsan A, Maciejewski JP, Sokol L, Epling-Burnette PK, Wei S, List AF. The relationship of TP53 R72P polymorphism to disease outcome and TP53 mutation in myelodysplastic syndromes. Blood Cancer J. 2015 Mar.5:e291. Pubmedid: 25768405. Pmcid: PMC4382654.
    • Horna P, Kurant D, Sokol L, Sotomayor EM, Moscinski L, Glass LF. Flow cytometric identification of immunophenotypically aberrant T-cell clusters on skin shave biopsy specimens from patients with mycosis fungoides. Am J Clin Pathol. 2015 Jun.143(6):785-796. Pubmedid: 25972320.
    • Roe C, Bennett J, Zhang L, Chavez J, Shah B, Sokol L, Komrokji R. Hemophagocytic Lymphohistiocytosis in Malignant Hematology: Uncommon but Should Not Be Forgotten?. Clin Lymphoma Myeloma Leuk. 2015 Jun.15 Suppl:S147-S150. Pubmedid: 26297268.
    • Dalia S, Suleiman Y, Croy DW, Sokol L. Association of Lymphomagenesis and the Reactivation of Hepatitis B Virus in Non-Hodgkin Lymphoma. Cancer Control. 2015 Jul.22(3):360-365. Pubmedid: 26351893.
    • Dalia S, Price S, Forsyth P, Sokol L, Jaglal M. What is the optimal dose of high-dose methotrexate in the initial treatment of primary central nervous system lymphoma?. Leuk Lymphoma. 2015 Feb.56(2):500-502. Pubmedid: 24882264.
    • Dalia S, Dunker K, Sokol L, Mhaskar R. Hepatitis B seropositivity and risk of developing multiple myeloma or Hodgkin lymphoma: A meta-analysis of observational studies. Leuk Res. 2015 Dec.39(12):1325-1333. Pubmedid: 26394533.
    • Braue J, Hagele T, Yacoub AT, Mannivanan S, Sokol L, Glass F, Greene JN. A case of rupioid syphilis masquerading as aggressive cutaneous lymphoma. Mediterr J Hematol Infect Dis. 2015 Apr.7(1):e2015026. Pubmedid: 25960854. Pmcid: PMC4418386.
    • Horwitz S, Coiffier B, Foss F, Prince HM, Sokol L, Greenwood M, Caballero D, Morschhauser F, Pinter-Brown L, Iyer SP, Shustov A, Nichols J, Balser J, Balser B, Pro B. Utility of ¹⁸fluoro-deoxyglucose positron emission tomography for prognosis and response assessments in a phase 2 study of romidepsin in patients with relapsed or refractory peripheral T-cell lymphoma. Ann Oncol. 2015 Apr.26(4):774-779. Pubmedid: 25605745. Pmcid: PMC4374388.
    • Zelenetz AD, Gordon LI, Wierda WG, Abramson JS, Advani RH, Andreadis CB, Bartlett N, Byrd JC, Czuczman MS, Fayad LE, Fisher RI, Glenn MJ, Harris NL, Hoppe RT, Horwitz SM, Kelsey CR, Kim YH, Krivacic S, LaCasce AS, Nademanee A, Porcu P, Press O, Rabinovitch R, Reddy N, Reid E, Saad AA, Sokol L, Swinnen LJ, Tsien C, Vose JM, Yahalom J, Zafar N, Dwyer M, Sundar H. Non-Hodgkin's lymphomas, version 4.2014. J Natl Compr Canc Ne. 2014 Sep.12(9):1282-1303. Pubmedid: 25190696. Pmcid: PMC4839265.
    • Luria L, Nguyen J, Zhou J, Jaglal M, Sokol L, Messina JL, Coppola D, Zhang L. Manifestations of gastrointestinal plasmablastic lymphoma: a case series with literature review. World J Gastroenterol. 2014 Sep.20(33):11894-11903. Pubmedid: 25206297. Pmcid: PMC4155383.
    • Foss F, Coiffier B, Horwitz S, Pro B, Prince HM, Sokol L, Greenwood M, Lerner A, Caballero D, Baran E, Kim E, Nichols J, Balser B, Wolfson J, Whittaker S. Tolerability to romidepsin in patients with relapsed/refractory T-cell lymphoma. Biomark Res. 2014 Sep.2:16. Pubmedid: 25279222. Pmcid: PMC4181623.
    • Zhang L, Ramchandren RM, Papenhausen P, Loughran TP, Sokol L. Transformed aggressive γδ-variant T-cell large granular lymphocytic leukemia with acquired copy neutral loss of heterozygosity at 17q11.2q25.3 and additional aberrations. Eur J Haematol. 2014 Sep.93(3):260-264. Pubmedid: 24635703.
    • Zhang L, Zhou J, Sokol L. Hereditary and acquired hemophagocytic lymphohistiocytosis. Cancer Control. 2014 Oct.21(4):301-312. Pubmedid: 25310211.
    • Riaz W, Zhang L, Horna P, Sokol L. Blastic plasmacytoid dendritic cell neoplasm: update on molecular biology, diagnosis, and therapy. Cancer Control. 2014 Oct.21(4):279-289. Pubmedid: 25310209.
    • Deaver D, Horna P, Cualing H, Sokol L. Pathogenesis, diagnosis, and management of Kikuchi-Fujimoto disease. Cancer Control. 2014 Oct.21(4):313-321. Pubmedid: 25310212.
    • Dalia S, Sagatys E, Sokol L, Kubal T. Rosai-Dorfman disease: tumor biology, clinical features, pathology, and treatment. Cancer Control. 2014 Oct.21(4):322-327. Pubmedid: 25310213.
    • Dalia S, Shao H, Sagatys E, Cualing H, Sokol L. Dendritic cell and histiocytic neoplasms: biology, diagnosis, and treatment. Cancer Control. 2014 Oct.21(4):290-300. Pubmedid: 25310210.
    • Sokol L. Hope for orphan lymphoproliferative and histiocytic diseases on the horizon?. Cancer Control. 2014 Oct.21(4):260-261. Pubmedid: 25310207.
    • Dalia S, Jaglal M, Chervenick P, Cualing H, Sokol L. Clinicopathologic characteristics and outcomes of histiocytic and dendritic cell neoplasms: the moffitt cancer center experience over the last twenty five years. Cancers (Basel). 2014 Nov.6(4):2275-2295. Pubmedid: 25405526. Pmcid: PMC4276966.
    • Horna P, Deaver DM, Qin D, Moscinski LC, Sotomayor EM, Glass LF, Sokol L. Quantitative flow cytometric identification of aberrant T cell clusters in erythrodermic cutaneous T cell lymphoma. Implications for staging and prognosis. J Clin Pathol. 2014 May.67(5):431-436. Pubmedid: 24319102.
    • Verstovsek S, Tam CS, Wadleigh M, Sokol L, Smith CC, Bui LA, Song C, Clary DO, Olszynski P, Cortes J, Kantarjian H, Shah NP. Phase I evaluation of XL019, an oral, potent, and selective JAK2 inhibitor. Leuk Res. 2014 Mar.38(3):316-322. Pubmedid: 24374145. Pmcid: PMC4414320.
    • Deaver D, Cauthen A, Cohen G, Sokol L, Glass F. Excimer laser in the treatment of mycosis fungoides. J Am Acad Dermatol. 2014 Jun.70(6):1058-1060. Pubmedid: 24775402.
    • Zelenetz AD, Gordon LI, Wierda WG, Abramson JS, Advani RH, Andreadis CB, Bartlett N, Bellam N, Byrd JC, Czuczman MS, Fayad LE, Fisher RI, Glenn MJ, Harris NL, Hoppe RT, Horwitz SM, Kelsey CR, Kim YH, Krivacic S, LaCasce AS, Nademanee A, Porcu P, Press O, Rabinovitch R, Reddy N, Reid E, Sokol L, Swinnen LJ, Tsien C, Vose JM, Yahalom J, Zafar N, Dwyer M, Sundar H. Non-Hodgkin's lymphomas, version 2.2014. J Natl Compr Canc Ne. 2014 Jun.12(6):916-946. Pubmedid: 24925202.
    • Yadav BS, George P, Sharma SC, Gorsi U, McClennan E, Martino MA, Chapman J, Chen LM, Prakash G, Malhotra P, Tantravahi SK, Glenn MJ, Werner TL, Baksh K, Sokol L, Morris GJ. Primary non-Hodgkin lymphoma of the ovary. Semin Oncol. 2014 Jun.41(3):e19-e30. Pubmedid: 25023360.
    • Wu H, Zhang L, Shao H, Sokol L, Sotomayor E, Letson D, Bui MM. Prognostic significance of soft tissue extension, international prognostic index, and multifocality in primary bone lymphoma: a single institutional experience. Brit J Haematol. 2014 Jul.166(1):60-68. Pubmedid: 24673481.
    • Coiffier B, Pro B, Prince HM, Foss F, Sokol L, Greenwood M, Caballero D, Morschhauser F, Wilhelm M, Pinter-Brown L, Padmanabhan Iyer S, Shustov A, Nielsen T, Nichols J, Wolfson J, Balser B, Horwitz S. Romidepsin for the treatment of relapsed/refractory peripheral T-cell lymphoma: pivotal study update demonstrates durable responses. J Hematol Oncol. 2014 Jan.7:11. Pubmedid: 24456586. Pmcid: PMC4016573.
    • Deaver D, Naghashpour M, Sokol L. Kikuchi-fujimoto disease in the United States: three case reports and review of the literature [corrected]. Mediterr J Hematol Infect Dis. 2014 Jan.6(1):e2014001. Pubmedid: 24455110. Pmcid: PMC3894840.
    • Wu H, Bui MM, Leston DG, Shao H, Sokol L, Sotomayor EM, Zhang L. Clinical characteristics and prognostic factors of bone lymphomas: focus on the clinical significance of multifocal bone involvement by primary bone large B-cell lymphomas. BMC Cancer. 2014 Dec.14:900. Pubmedid: 25465716. Pmcid: PMC4265495.
    • Harrington L, Sokol L, Holdener S, Shao H, Zhang L. Cutaneous gamma-delta T-cell lymphoma with central nervous system involvement: report of a rarity with review of literature. J Cutan Pathol. 2014 Dec.41(12):936-943. Pubmedid: 25292289.
    • McGraw KL, Basiorka AA, Johnson JO, Clark J, Caceres G, Padron E, Heaton R, Ozawa Y, Wei S, Sokol L, List AF. Lenalidomide induces lipid raft assembly to enhance erythropoietin receptor signaling in myelodysplastic syndrome progenitors. PLoS One. 2014 Dec.9(12):e114249. Pubmedid: 25469886. Pmcid: PMC4254997.
    • Dalia S, Chavez J, Little B, Bello C, Fisher K, Lee JH, Chervenick P, Sokol L, Sotomayor E, Shah B. Serum albumin retains independent prognostic significance in diffuse large B-cell lymphoma in the post-rituximab era. Ann Hematol. 2014 Aug.93(8):1305-1312. Pubmedid: 24590536.
    • Dalia S, Forsyth P, Chavez J, Price S, Shah B, Bello C, Sokol L, Pan E, Sotomayor E, Lee JH, Fisher K, Jaglal M. Primary B-cell CNS lymphoma clinicopathologic and treatment outcomes in 89 patients from a single tertiary care center. Int J Hematol. 2014 Apr.99(4):450-456. Pubmedid: 24584873.
    • Dalia S, Chavez J, Castillo JJ, Sokol L. Hepatitis B infection increases the risk of non-Hodgkin lymphoma: a meta-analysis of observational studies. Leuk Res. 2013 Sep.37(9):1107-1115. Pubmedid: 23809055.
    • Mailloux AW, Zhang L, Moscinski L, Bennett JM, Yang L, Yoder SJ, Bloom G, Wei C, Wei S, Sokol L, Loughran TP, Epling-Burnette PK. Fibrosis and subsequent cytopenias are associated with basic fibroblast growth factor-deficient pluripotent mesenchymal stromal cells in large granular lymphocyte leukemia. J Immunol. 2013 Oct.191(7):3578-3593. Pubmedid: 24014875. Pmcid: PMC4346227.
    • Caceres G, McGraw K, Yip BH, Pellagatti A, Johnson J, Zhang L, Liu K, Zhang LM, Fulp WJ, Lee JH, Al Ali NH, Basiorka A, Smith LJ, Daugherty FJ, Littleton N, Wells RA, Sokol L, Wei S, Komrokji RS, Boultwood J, List AF. TP53 suppression promotes erythropoiesis in del(5q) MDS, suggesting a targeted therapeutic strategy in lenalidomide-resistant patients. Proc Natl Acad Sci U S A. 2013 Oct.110(40):16127-16132. Pubmedid: 24043769. Pmcid: PMC3791697.
    • Horna P, Hamill JR, Sokol L, Glass LF. Primary cutaneous plasmablastic lymphoma in an immunocompetent patient. J Am Acad Dermatol. 2013 Nov.69(5):e274-e276. Pubmedid: 24124865.
    • Patel J, Ho M, Ho V, Bello C, Djulbegovic B, Sokol L, Wetzstein G. Rapid infusion rituximab for maintenance therapy: is it feasible?. Leuk Res Treatment. 2013 Nov.2013:629283. Pubmedid: 24288618. Pmcid: PMC3833187.
    • Zhang Y, Zhang L, Jin X, Zhao H, Hao X, Peker D, Wei S, Sokol L, Moscinski L. Bone marrow involvement as initial presentation of CD8 cytotoxic peripheral T-cell lymphoma with CD20 coexpression and relatively indolent clinical course. Leuk Lymphoma. 2013 May.54(5):1113-1116. Pubmedid: 23035635.
    • Zelenetz AD, Wierda WG, Abramson JS, Advani RH, Andreadis CB, Bartlett N, Bellam N, Byrd JC, Czuczman MS, Fayad LE, Glenn MJ, Gockerman JP, Gordon LI, Harris NL, Hoppe RT, Horwitz SM, Kelsey CR, Kim YH, Krivacic S, Lacasce AS, Nademanee A, Porcu P, Press O, Pro B, Reddy N, Sokol L, Swinnen L, Tsien C, Vose JM, Yahalom J, Zafar N, Dwyer MA, Naganuma M. Non-Hodgkin's lymphomas, version 1.2013. J Natl Compr Canc Ne. 2013 Mar.11(3):257-272. Pubmedid: 23486452.
    • Venner CP, Woltosz JW, Nevill TJ, Deeg HJ, Caceres G, Platzbecker U, Scott BL, Sokol L, Sung S, List AF, Karsan A. Correlation of clinical response and response duration with miR-145 induction by lenalidomide in CD34(+) cells from patients with del(5q) myelodysplastic syndrome. Haematologica. 2013 Mar.98(3):409-413. Pubmedid: 22929976. Pmcid: PMC3659949.
    • Kurzrock R, Voorhees PM, Casper C, Furman RR, Fayad L, Lonial S, Borghaei H, Jagannath S, Sokol L, Usmani SZ, van de Velde H, Qin X, Puchalski TA, Hall B, Reddy M, Qi M, van Rhee F. A phase I, open-label study of siltuximab, an anti-IL-6 monoclonal antibody, in patients with B-cell non-Hodgkin lymphoma, multiple myeloma, or Castleman disease. Clin Cancer Res. 2013 Jul.19(13):3659-3670. Pubmedid: 23659971.
    • Zhang L, Sotomayor EM, Papenhausen PR, Shao H, Moscinski LC, Sandin RL, Caceres G, Valenica H, Malafa M, List AF, Sokol L. Unusual concurrence of T-cell large granular lymphocytic leukemia with Franklin disease (gamma heavy chain disease) manifested with massive splenomegaly. Leuk Lymphoma. 2013 Jan.54(1):205-208. Pubmedid: 22694793.
    • Wei S, Chen X, McGraw K, Zhang L, Komrokji R, Clark J, Caceres G, Billingsley D, Sokol L, Lancet J, Fortenbery N, Zhou J, Eksioglu EA, Sallman D, Wang H, Epling-Burnette PK, Djeu J, Sekeres M, Maciejewski JP, List A. Lenalidomide promotes p53 degradation by inhibiting MDM2 auto-ubiquitination in myelodysplastic syndrome with chromosome 5q deletion. Oncogene. 2013 Feb.32(9):1110-1120. Pubmedid: 22525275. Pmcid: PMC3751397.
    • Phillips KM, Pinilla-Ibarz J, Sotomayor E, Lee MR, Jim HS, Small BJ, Sokol L, Lancet J, Tinsley S, Sweet K, Komrokji R, Jacobsen PB. Quality of life outcomes in patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors: a controlled comparison. Support Care Cancer. 2013 Apr.21(4):1097-1103. Pubmedid: 23179489.
    • Sokol L, Cripe L, Kantarjian H, Sekeres MA, Parmar S, Greenberg P, Goldberg SL, Bhushan V, Shammo J, Hohl R, Verma A, Garcia-Manero G, Li YP, Lowe A, Zhu J, List AF. Randomized, dose-escalation study of the p38α MAPK inhibitor SCIO-469 in patients with myelodysplastic syndrome. Leukemia. 2013 Apr.27(4):977-980. Pubmedid: 23032694.
    • Bhagat TD, Zhou L, Sokol L, Kessel R, Caceres G, Gundabolu K, Tamari R, Gordon S, Mantzaris I, Jodlowski T, Yu Y, Jing X, Polineni R, Bhatia K, Pellagatti A, Boultwood J, Kambhampati S, Steidl U, Stein C, Ju W, Liu G, Kenny P, List A, Bitzer M, Verma A. miR-21 mediates hematopoietic suppression in MDS by activating TGF-β signaling. Blood. 2013 Apr.121(15):2875-2881. Pubmedid: 23390194. Pmcid: PMC3624935.
    • Nyland SB, Krissinger DJ, Clemente MJ, Irby RB, Baab KT, Jarbadan NR, Sokol L, Schaefer E, Liao J, Cuthbertson D, Epling-Burnette P, Paquette R, List AF, Maciejewski JP, Loughran TP. Seroreactivity to LGL leukemia-specific epitopes in aplastic anemia, myelodysplastic syndrome and paroxysmal nocturnal hemoglobinuria: results of a bone marrow failure consortium study. Leuk Res. 2012 May.36(5):581-587. Pubmedid: 22386729. Pmcid: PMC3312981.
    • Sugimori C, Padron E, Caceres G, Shain K, Sokol L, Zhang L, Tiu R, O'Keefe CL, Afable M, Clemente M, Lee JM, Maciejewski JP, List AF, Epling-Burnette PK, Araten DJ. Paroxysmal nocturnal hemoglobinuria and concurrent JAK2(V617F) mutation. Blood Cancer J. 2012 Mar.2(3):e63. Pubmedid: 22829258. Pmcid: PMC3317526.
    • Tombleson RL, Ho V, Sokol L, Pinilla J, Wetzstein GA. Optimizing premedications in the prevention of bendamustine infusion-related reactions. Cancer Control. 2012 Jul.19(3):245-247. Pubmedid: 22710900.
    • Sokol L, Naghashpour M, Glass LF. Primary cutaneous B-cell lymphomas: recent advances in diagnosis and management. Cancer Control. 2012 Jul.19(3):236-244. Pubmedid: 22710899.
    • Bello C, Sokol L. B-cell non-hodgkin lymphoma: targeting in on the future. Cancer Control. 2012 Jul.19(3):171-172. Pubmedid: 22710892.
    • Coiffier B, Pro B, Prince HM, Foss F, Sokol L, Greenwood M, Caballero D, Borchmann P, Morschhauser F, Wilhelm M, Pinter-Brown L, Padmanabhan S, Shustov A, Nichols J, Carroll S, Balser J, Balser B, Horwitz S. Results from a pivotal, open-label, phase II study of romidepsin in relapsed or refractory peripheral T-cell lymphoma after prior systemic therapy. J Clin Oncol. 2012 Feb.30(6):631-636. Pubmedid: 22271479.
    • Zelenetz AD, Wierda WG, Abramson JS, Advani RH, Andreadis CB, Bartlett N, Bellam N, Byrd JC, Czuczman MS, Fayad L, Glenn MJ, Gockerman JP, Gordon LI, Harris NL, Hoppe RT, Horwitz SM, Kelsey CR, Kim YH, Krivacic S, LaCasce AS, Nademanee A, Porcu P, Press O, Pro B, Reddy N, Sokol L, Swinnen L, Tsien C, Vose JM, Yahalom J, Zafar N, Naganuma M, Dwyer MA. Non-Hodgkin's Lymphomas, version 3.2012. J Natl Compr Canc Ne. 2012 Dec.10(12):1487-1498. Pubmedid: 23221787.
    • Caceres G, Robey RW, Sokol L, McGraw KL, Clark J, Lawrence NJ, Sebti SM, Wiese M, List AF. HG-829 is a potent noncompetitive inhibitor of the ATP-binding cassette multidrug resistance transporter ABCB1. Cancer Res. 2012 Aug.72(16):4204-4213. Pubmedid: 22761337. Pmcid: PMC4557794.
    • McGraw KL, Fuhler GM, Johnson JO, Clark JA, Caceres GC, Sokol L, List AF. Erythropoietin receptor signaling is membrane raft dependent. PLoS One. 2012 Aug.7(4):e34477. Pubmedid: 22509308. Pmcid: PMC3317978.
    • Bai F, Villagra AV, Zou J, Painter JS, Connolly K, Blaskovich MA, Sokol L, Sebti S, Djeu JY, Loughran TP, Wei S, Sotomayor E, Epling-Burnette P. Tipifarnib-mediated suppression of T-bet-dependent signaling pathways. Cancer Immunol Immun. 2012 Apr.61(4):523-533. Pubmedid: 21983879. Pmcid: PMC4612510.
    • Sokol L. Fox and Blimp in NK-cell lymphoma. Blood. 2011 Sep.118(12):3192-3193. Pubmedid: 21940827.
    • Zelenetz AD, Abramson JS, Advani RH, Andreadis CB, Bartlett N, Bellam N, Byrd JC, Czuczman MS, Fayad LE, Glenn MJ, Gockerman JP, Gordon LI, Harris NL, Hoppe RT, Horwitz SM, Kelsey CR, Kim YH, Lacasce AS, Nademanee A, Porcu P, Press O, Pro B, Reddy N, Sokol L, Swinnen LJ, Tsien C, Vose JM, Wierda WG, Yahalom J, Zafar N. Non-Hodgkin's lymphomas. J Natl Compr Canc Ne. 2011 May.9(5):484-560. Pubmedid: 21550968.
    • Komrokji RS, Al Ali NH, Beg MS, Safa MM, Rollison D, Kharfan-Dabaja M, Bello C, Cultrera J, Sokol L, Pinilla-Ibarz J, Sotomayor EM. Outcome of diffuse large B-Cell lymphoma in the United States has improved over time but racial disparities remain: review of SEER data. Clin Lymphoma Myeloma Leuk. 2011 Jun.11(3):257-260. Pubmedid: 21658652.
    • Zhou L, McMahon C, Bhagat T, Alencar C, Yu Y, Fazzari M, Sohal D, Heuck C, Gundabolu K, Ng C, Mo Y, Shen W, Wickrema A, Kong G, Friedman E, Sokol L, Mantzaris I, Mantzaris G, Pellagatti A, Boultwood J, Platanias LC, Steidl U, Yan L, Yingling JM, Lahn MM, List A, Bitzer M, Verma A. Reduced SMAD7 leads to overactivation of TGF-beta signaling in MDS that can be reversed by a specific inhibitor of TGF-beta receptor I kinase. Cancer Res. 2011 Feb.71(3):955-963. Pubmedid: 21189329. Pmcid: PMC3032816.
    • Liu JJ, Zhang L, Ayala E, Field T, Ochoa-Bayona JL, Perez L, Bello CM, Chervenick PA, Bruno S, Cultrera JL, Baz RC, Kharfan-Dabaja MA, Raychaudhuri J, Sotomayor EM, Sokol L. Human immunodeficiency virus (HIV)-negative plasmablastic lymphoma: a single institutional experience and literature review. Leuk Res. 2011 Dec.35(12):1571-1577. Pubmedid: 21752466.
    • Naghashpour M, Setoodeh R, Moscinski L, Bergier G, McCardle T, Glass F, Sokol L. Nonnecrobiotic necrobiotic xanthogranuloma as an initial manifestation of paraproteinemia and small lymphocytic lymphoma in a patient with Sjögren syndrome. Am J Dermatopathxxx. 2011 Dec.33(8):855-857. Pubmedid: 22042261.
    • Sokol L, Caceres G, Volinia S, Alder H, Nuovo GJ, Liu CG, McGraw K, Clark JA, Sigua CA, Chen DT, Moscinski L, Croce CM, List AF. Identification of a risk dependent microRNA expression signature in myelodysplastic syndromes. Brit J Haematol. 2011 Apr.153(1):24-32. Pubmedid: 21332710. Pmcid: PMC4294220.
    • Johns ME, Moscinski LC, Sokol L. Phenytoin-associated lymphoadenopathy mimicking a peripheral T-cell lymphoma. Mediterr J Hematol Infect Dis. 2010 Sep.2(2):e2010028. Pubmedid: 21415974. Pmcid: PMC3033141.
    • Hartley MA, Sokol L, Caceres G, Hussein MA, List A, Pinilla-Ibarz J. Monoclonal gammopathy of undetermined significance disguised as chronic neutrophilic leukemia. Mediterr J Hematol Infect Dis. 2010 Mar.2(1):e2010002. Pubmedid: 21415944. Pmcid: PMC3033111.
    • Zelenetz AD, Abramson JS, Advani RH, Andreadis CB, Byrd JC, Czuczman MS, Fayad L, Forero A, Glenn MJ, Gockerman JP, Gordon LI, Harris NL, Hoppe RT, Horwitz SM, Kaminski MS, Kim YH, Lacasce AS, Mughal TI, Nademanee A, Porcu P, Press O, Prosnitz L, Reddy N, Smith MR, Sokol L, Swinnen L, Vose JM, Wierda WG, Yahalom J, Yunus F. NCCN Clinical Practice Guidelines in Oncology: non-Hodgkin's lymphomas. J Natl Compr Canc Ne. 2010 Mar.8(3):288-334. Pubmedid: 20202462.
    • Sokol L, Caceres G, Rocha K, Stockero KJ, Dewald DW, List AF. JAK2(V617F) mutation in myelodysplastic syndrome (MDS) with del(5q) arises in genetically discordant clones. Leuk Res. 2010 Jun.34(6):821-823. Pubmedid: 19819015.
    • van Rhee F, Fayad L, Voorhees P, Furman R, Lonial S, Borghaei H, Sokol L, Crawford J, Cornfeld M, Qi M, Qin X, Herring J, Casper C, Kurzrock R. Siltuximab, a novel anti-interleukin-6 monoclonal antibody, for Castleman's disease. J Clin Oncol. 2010 Aug.28(23):3701-3708. Pubmedid: 20625121.
    • Kiss R, Polgár T, Kirabo A, Sayyah J, Figueroa NC, List AF, Sokol L, Zuckerman KS, Gali M, Bisht KS, Sayeski PP, Keseru GM. Identification of a novel inhibitor of JAK2 tyrosine kinase by structure-based virtual screening. Bioorg Med Chem Lett. 2009 Jul.19(13):3598-3601. Pubmedid: 19447617. Pmcid: PMC2812898.
    • Wei S, Chen X, Rocha K, Epling-Burnette PK, Djeu JY, Liu Q, Byrd J, Sokol L, Lawrence N, Pireddu R, Dewald G, Williams A, Maciejewski J, List A. A critical role for phosphatase haplodeficiency in the selective suppression of deletion 5q MDS by lenalidomide. Proc Natl Acad Sci U S A. 2009 Aug.106(31):12974-12979. Pubmedid: 19470455. Pmcid: PMC2722346.
    • Chen X, Bai F, Sokol L, Zhou J, Ren A, Painter JS, Liu J, Sallman DA, Chen YA, Yoder JA, Djeu JY, Loughran TP, Epling-Burnette PK, Wei S. A critical role for DAP10 and DAP12 in CD8+ T cell-mediated tissue damage in large granular lymphocyte leukemia. Blood. 2009 Apr.113(14):3226-3234. Pubmedid: 19075187. Pmcid: PMC2665892.
    • Alekshun T, Rezania D, Ayala E, Cualing H, Sokol L. Skeletal muscle peripheral T-cell lymphoma. J Clin Oncol. 2008 Jan.26(3):501-503. Pubmedid: 18202425.
    • Epling-Burnette PK, Sokol L, Chen X, Bai F, Zhou J, Blaskovich MA, Zou J, Painter JS, Edwards TD, Moscinski L, Yoder JA, Djeu JY, Sebti S, Loughran TP, Wei S. Clinical improvement by farnesyltransferase inhibition in NK large granular lymphocyte leukemia associated with imbalanced NK receptor signaling. Blood. 2008 Dec.112(12):4694-4698. Pubmedid: 18791165. Pmcid: PMC2597136.
    • Sokol L, Loughran TP. Large granular lymphocyte leukemia. Curr Hematol Malig Rep. 2007 Oct.2(4):278-282. Pubmedid: 20425381.
    • Sokol L, List A. Immunomodulatory therapy for myelodysplastic syndromes. Int J Hematol. 2007 Nov.86(4):301-305. Pubmedid: 18055335.
    • Alekshun T, Tao J, Sokol L. Aggressive T-cell large granular lymphocyte leukemia: a case report and review of the literature. Am J Hematol. 2007 Jun.82(6):481-485. Pubmedid: 17205534.
    • Rezania D, Sokol L, Cualing H. Classification and treatment of rare and aggressive types of peripheral T-cell/natural killer-cell lymphomas of the skin. Cancer Control. 2007 Apr.14(2):112-123. Pubmedid: 17387296.
    • Alekshun T, Sokol L. Diseases of large granular lymphocytes. Cancer Control. 2007 Apr.14(2):141-150. Pubmedid: 17387299.
    • Behera M, Kumar A, Soares H, Sokol L, Djulbegovic B. Evidence-based medicine for rare diseases: implications for data interpretation and clinical trial design. Cancer Control. 2007 Apr.14(2):160-166. Pubmedid: 17387301.
    • Rezania D, Sokol L, Cualing H. Classification and treatment of rare and aggressive types of peripheral T-cell/natural killer-cell lymphomas of the skin. Cancer Control. 2007 Apr.14(2):112-123.
    • Sokol L, Loughran TP J. Large granular lymphocyte leukemia. Oncologist. 2006 Mar.11(3):263-273. Pubmedid: 16549811.
    • Naing A, Sokol L, List A. Developmental therapeutics for myelodysplastic syndromes. J Natl Compr Canc Ne. 2006 Jan.4(1):78-82. Pubmedid: 16403406.
    • Alekshun T, Lundbye J, Sokol L, Dailey M. Use of bivalirudin to treat heparin-induced thrombocytopenia in a patient with idiopathic giant-cell myocarditis. Conn Med. 2006 Feb.70(2):69-71. Pubmedid: 16768056.
    • Kurtin S, Sokol L. Practical considerations in the use of lenalidomide therapy for myelodysplastic syndromes. Cancer Control. 2006 Dec.13 Suppl:26-31. Pubmedid: 17242664.
    • Navas TA, Mohindru M, Estes M, Ma JY, Sokol L, Pahanish P, Parmar S, Haghnazari E, Zhou L, Collins R, Kerr I, Nguyen AN, Xu Y, Platanias LC, List AF, Higgins LS, Verma A. Inhibition of overactivated p38 MAPK can restore hematopoiesis in myelodysplastic syndrome progenitors. Blood. 2006 Dec.108(13):4170-4177. Pubmedid: 16940419. Pmcid: PMC1895446.
    • Sokol L, Agrawal D, Loughran TP Jr.. Characterization of HTLV envelope seroreactivity in large granular lymphocyte leukemia. Leuk Res. 2005 Apr.29(4):381-387. Pubmedid: 15725471.
    • Sokol L, Agosti SJ. Simultaneous manifestation of chronic lymphocytic leukemia (CLL) and hairy cell leukemia (HCL). Am J Hematol. 2004 Feb.75(2):107-109. Pubmedid: 14755378.
    • Sokol L, Loughran TP J. Large granular lymphocyte leukemia and natural killer cell leukemia/lymphomas. CURR TREAT OPTION ON. 2003 Aug.4(4):289-296. Pubmedid: 12943609.
    • McIlwain L, Sokol L, Moscinski L, Saba H. Acute myeloid leukemia mimicking primary testicular neoplasm. Presentation of a case with review of literature. Eur J Haematol. 2003 Apr.70(4):242-245. Pubmedid: 12656749.
    • Sokol L, Stueben ET, Jaikishen J, Lamarche MB. Turner syndrome associated with acquired von Willebrand disease, primary biliary cirrhosis, and inflammatory bowel disease. Am J Hematol. 2002 Jul.70(3):257-259. Pubmedid: 12116986.
    • Sokol L, Prchal J. Pure red-cell aplasia and recombinant erythropoietin. N Engl J Med. 2002.346(20):1584-1586. Pubmedid: 12017159.
  • Grants

    Title: Targetable Epidgenetic Mechanism Driving Cutaneous T Cell Lymphoma
    Sponsor: Nat Institutes of Health
    PI (MPI): Pinilla, J., PI (MPI): Sokol, L.
  • Patient Comments

    Overall Satisfaction

    4.8

    119 patients rated this provider

    The Provider Rating is an average of all responses to specific care provider-related questions from our nationally-recognized Press Ganey Patient Satisfaction Survey. Responses are measured on a scale of 1 to 5 with 5 being the best score.

    Patients that are treated in outpatient or hospital environments may receive different surveys, and the volume of responses will vary by question.

    Learn more about our patient satisfaction survey

     

    Comments

    Comments are gathered from specific care provider-related questions from our Patient Satisfaction Survey . The comments are submitted by patients and reflect their views and opinions. Patients are de-identified for confidentiality and patient privacy.

    We post both positive and negative comments from the surveys. We do not post comments that are libelous, slanderous, profane, irrelevant or otherwise inappropriate or may risk the privacy of our patients. A “[…]” in the comments below indicates de-identified patient information or comments that are unrelated to the patient’s experience with the visit to the provider, such as comments related to another provider, about the survey itself, or otherwise completely off-topic.

    Not all providers will have a star rating or comments. In order to ensure accuracy of our ratings, we only display ratings for providers who have a minimum of 30 completed from the previous 12 months.

    Learn more about our patient comments

    Provider Ratings and comments are gathered from our nationally-recognized Press Ganey Patient Satisfaction Survey. If a provider does not have ratings or comments listed it can be for several reasons, including:

    • The provider has not yet received the minimum number of patient satisfaction surveys to be eligible for display. We require a minimum of 30 surveys before we post results to ensure that the rating is statistically reliable and a true reflection of patient satisfaction.
    • He or she may be a researcher or other type of provider that does not see patients.
    • The provider practices in a specialty or office that does not use the specified surveys currently used for these ratings.

    Learn more about our patient satisfaction survey, ratings and comments

Find a Doctor